Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Henagliflozin on Myocardial Fibrosis in Obese Patients (LY2026-317-C)

14. november 2026 opdateret af: Jing Ma

Effect of Henagliflozin on Myocardial Fibrosis in Obese Patients: A Prospective, Randomized, Controlled Study.

This study evaluates the anti-fibrotic efficacy and safety of henagliflozin versus metformin in non-diabetic obese patients with subclinical myocardial fibrosis, explores whether the benefit is mediated by metabolic improvement or direct myocardial protection, and aims to provide high-level evidence for early pharmacological intervention.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This study will be based on an established specialized cohort of non-diabetic patients with simple obesity and a multi-omics database. By integrating clinical data with multidimensional information including genomics, metabolomics, and proteomics, patients at high risk of myocardial fibrosis will be identified. After myocardial fibrotic changes are further confirmed by CMR, eligible participants will be randomly assigned to the control group (metformin) or the intervention group (henagliflozin). The treatment period will be 24 weeks, followed by a 24-week safety follow-up period. The difference in the change in the degree of myocardial fibrosis before and after treatment between the two groups will be compared to determine the efficacy of henagliflozin in counteracting myocardial fibrosis in the non-diabetic obese population. This project aims to provide high-level evidence-based medical evidence for targeted pharmacological intervention of obesity-related early cardiac damage, with the goal of improving the long-term prognosis of this population.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

100

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. BMI ≥ 28 kg/m², or waist circumference ≥ 90 cm in men or ≥ 85 cm in women, or body fat percentage ≥ 25% in men or ≥ 30% in women;
  2. Adults aged 18 to 65 years;
  3. ECV greater than 30%;
  4. No participation in other clinical trials within the past three months.

Exclusion Criteria:

  1. Diagnosed with diabetes mellitus or prediabetes;
  2. History of coronary artery disease (coronary stenosis > 50% on coronary angiography or coronary computed tomography), history of myocardial infarction, history of coronary artery bypass grafting or percutaneous coronary intervention; non-ischemic cardiovascular diseases such as idiopathic cardiomyopathy, valvular disease, congenital heart disease, or cor pulmonale; arrhythmia or bundle branch block on electrocardiogram; implantation of a cardiac pacemaker or defibrillator;
  3. Uncontrolled hypertension: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg during the screening visit (mean of three blood pressure measurements in the supine position);
  4. Symptomatic hypotension and/or systolic blood pressure < 90 mmHg at V1 or V2, or patients judged by the clinician to have hypovolemia;
  5. Use within 3 months of: 1) medications that may affect body weight or glucose metabolism, including systemic glucocorticoids (excluding topical, ophthalmic, nasal spray, or inhaled preparations; excluding low-dose or overnight dexamethasone suppression test use), growth hormone, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic/tetracyclic antipsychotic drugs, other psychiatric medications or sedatives (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts), etc.; 2) traditional Chinese medicines, Chinese patent medicines, herbal medicines, health supplements, meal replacements, etc., with weight-loss or glucose-lowering effects; 3) use of or current use of the following weight-loss drugs or drugs containing the following ingredients, such as: sibutramine hydrochloride, orlistat, phentermine, phenylpropanolamine, clobenzorex, fenfluramine, amfepramone, lorcaserin, phentermine/topiramate combination, naltrexone/bupropion combination, etc.; 4) use of glucose-lowering drugs, such as metformin, α-glucosidase inhibitors, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, thiazolidinediones (TZDs), insulin, etc.;
  6. Other endocrine and metabolic diseases such as hyperthyroidism, hypothyroidism, acromegaly, diabetes insipidus, or Cushing's syndrome;
  7. Concurrent malignant tumors;
  8. Severe liver disease (Child-Pugh class C) or liver enzymes (ALT/AST) > 3 times the upper limit of normal;
  9. Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m²;
  10. Cognitive impairment, or concomitant infectious or autoimmune diseases;
  11. History of recurrent urinary or reproductive tract infections;
  12. Patients who refuse henagliflozin or metformin treatment, or who are allergic to henagliflozin, metformin, or their excipients; those with incomplete questionnaires or incomplete data;
  13. Pregnant or breastfeeding women.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Interventionsgruppe

Oral henagliflozin 10 mg once daily for 24 weeks, administered at a fixed dose without adjustment. Used in non-diabetic obese patients with subclinical myocardial fibrosis as an off-label investigational treatment.

Aktiv komparator: Control Group

oral metformin tablets 2000 mg/day; or the maximum tolerated dose (≥1000 mg/day).

Oral metformin titrated to 2000 mg/day (1000 mg twice daily), or the maximum tolerated dose (≥1000 mg/day), for 24 weeks. Dose titration: 500 mg twice daily for weeks 1-2, then 1000 mg twice daily from week 3 if tolerated.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from Baseline in Myocardial Extracellular Volume (ECV) Fraction at 24 Weeks
Tidsramme: Baseline to Week 24

Change from baseline in myocardial extracellular volume (ECV) fraction, as measured by cardiac magnetic resonance (CMR) T1 mapping pre- and post-contrast. ECV is calculated from pre- and post-contrast T1 relaxation times and the patient's hematocrit. The between-group difference in ΔECV (Henagliflozin vs. Metformin) will be compared; continuous data will be summarized as mean ± SD and analyzed using mixed-effects models.

Baseline to Week 24

Sekundære resultatmål

Resultatmål
Tidsramme
Change from Baseline in Epicardial Adipose Tissue (EAT) Volume at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Left Ventricular Ejection Fraction (LVEF) at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Cardiac Output at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Heart Rate at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Peak Filling Rate at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Stroke Volume Index (BSA-corrected) at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in End-Systolic Volume Index (BSA-corrected) at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in End-Diastolic Volume Index (BSA-corrected) at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Left Ventricular Mass Index (BSA-corrected) at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Early-to-Late Filling Ratio (E/A) at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in LV Mass to End-Diastolic Volume Ratio (MVR) at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Cardiac Index at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Body Weight at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Body Mass Index (BMI) at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Systolic Blood Pressure at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Diastolic Blood Pressure at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Glycated Hemoglobin (HbA1c) at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Fasting Plasma Glucose at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in HOMA-IR (Insulin Resistance Index) at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Total Cholesterol at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Triglycerides at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24
Change from Baseline in High-sensitivity CRP (hsCRP) at 24 Weeks
Tidsramme: Baseline to Week 24
Baseline to Week 24

Andre resultatmål

Resultatmål
Tidsramme
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Genitourinary Tract Infections
Tidsramme: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Gastrointestinal Adverse Events
Tidsramme: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Ketoacidosis
Tidsramme: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Serious Adverse Events (SAEs)
Tidsramme: Up to 48 Weeks
Up to 48 Weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Jing Ma, Department of Endocrinology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

1. oktober 2028

Studieafslutning (Anslået)

1. oktober 2028

Datoer for studieregistrering

Først indsendt

1. november 2026

Først indsendt, der opfyldte QC-kriterier

14. november 2026

Først opslået (Faktiske)

19. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • LY2026-317-C

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .